MCID: PPL021
MIFTS: 49

Papilledema

Categories: Eye diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Papilledema

MalaCards integrated aliases for Papilledema:

Name: Papilledema 12 74 52 29 54 15 71
Edema of the Optic Disc 52
Choked Disk 52

Classifications:



External Ids:

Disease Ontology 12 DOID:146
MeSH 43 D010211
NCIt 49 C3307
SNOMED-CT 67 73221001
UMLS 71 C0030353

Summaries for Papilledema

NIH Rare Diseases : 52 Papilledema is a condition in which increased pressure in or around the brain (intracranial pressure) causes swelling of the part of the optic nerve inside the eye (optic disc ). Symptoms of increased intracranial pressure include headache or nausea and vomiting. Vision problems are not common initially, but may include short flickers of gray vision, blurred or double vision, and decreased field of vision or ability to see colors. Both eyes are usually affected. Papilledema by definition is caused by increased cranial pressure. Diagnosis includes a thorough eye exam by an ophthalmologist . Brain imaging studies (for example CT scan or MRI ) are used to find the cause of the increased intracranial pressure. Treatment depends on the cause of the increased pressure but may include medications, surgery and/or weight management.

MalaCards based summary : Papilledema, also known as edema of the optic disc, is related to intracranial hypertension and optic papillitis, and has symptoms including edema An important gene associated with Papilledema is F2 (Coagulation Factor II, Thrombin), and among its related pathways/superpathways are Response to elevated platelet cytosolic Ca2+ and Folate Metabolism. The drugs Minocycline and Doxycycline have been mentioned in the context of this disorder. Affiliated tissues include brain, eye and spinal cord, and related phenotypes are homeostasis/metabolism and hematopoietic system

Wikipedia : 74 Papilledema or papilloedema is optic disc swelling that is caused by increased intracranial pressure due... more...

Related Diseases for Papilledema

Diseases related to Papilledema via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 779)
# Related Disease Score Top Affiliating Genes
1 intracranial hypertension 32.2 SERPINC1 F3 F2 APOH ALB
2 optic papillitis 31.6 NLRP3 CRP CD40LG CD4 ACE
3 hydrocephalus 31.6 VEGFA TP53 SYP ARSB ACE
4 thrombophilia due to thrombin defect 30.8 SERPINC1 F3 F2 APOH
5 lateral sinus thrombosis 30.6 SERPINC1 F2
6 intracranial hypertension, idiopathic 30.6 PCLO OGG1 F3 F2
7 thrombosis 30.6 SERPINC1 F3 F2 CD40LG APOH
8 sagittal sinus thrombosis 30.5 SERPINC1 F3 F2
9 orbital plasma cell granuloma 30.3 CRP CD40LG
10 cerebral sinovenous thrombosis 30.2 F3 F2 APOH
11 osteosclerotic myeloma 30.2 VEGFA MYOM2 CD40LG
12 meningitis 30.0 VEGFA NLRP3 CRP CD40LG ALB
13 brucellosis 30.0 IL1RN CRP CD40LG
14 arteritic anterior ischemic optic neuropathy 29.9 F2 ACE
15 macular retinal edema 29.9 VEGFA ALB ACE
16 syphilitic meningitis 29.9 SERPINC1 CD40LG CD4
17 asymptomatic neurosyphilis 29.9 CD40LG CD4
18 nonarteritic anterior ischemic optic neuropathy 29.8 VEGFA SERPINC1 F2 CRP ACE
19 cinca syndrome 29.8 NLRP3 IL1RN IL1R1 CRP
20 epidemic typhus 29.7 CRP CD40LG CD4
21 retinal vascular occlusion 29.7 VEGFA SERPINC1 F2 CRP APOH
22 multiple cranial nerve palsy 29.6 CRP ACE
23 central retinal vein occlusion 29.6 VEGFA SERPINC1 F3 F2 APOH
24 hemorrhagic disease 29.6 SERPINC1 F3 F2 CRP CD40LG
25 neuroretinitis 29.5 CRP CD40LG CD4 ACE
26 hemangioma 29.5 VEGFA TP53 SYP F3 F2
27 sleep apnea 29.4 VEGFA CRP ALB ACE
28 neurosarcoidosis 29.4 CRP CD4 ACE
29 homocysteinemia 29.4 SERPINC1 F2 CRP APOH ALB
30 acquired immunodeficiency syndrome 29.4 TP53 CRP CD40LG CD4 ALB
31 granulomatous angiitis 29.4 CRP ACE
32 apnea, obstructive sleep 29.3 VEGFA CRP ALB ACE
33 crohn's disease 29.3 NLRP3 CRP CD4 ALB
34 antiphospholipid syndrome 29.3 SERPINC1 F3 F2 CRP CD40LG APOH
35 carotid artery disease 29.3 F3 CRP ACE
36 thrombocytosis 29.3 SERPINC1 F3 F2 CRP ALB
37 hypertensive retinopathy 29.3 VEGFA CRP ALB ACE
38 pleural empyema 29.3 CRP CD40LG CD4 ALB
39 polyneuropathy 29.3 VEGFA CRP CD40LG ALB ACE
40 chorioretinitis 29.3 VEGFA CD40LG CD4 ACE
41 meningoencephalitis 29.3 CRP CD40LG CD4 ALB
42 arthritis 29.2 VEGFA IL1RN IL1R1 CRP ALB
43 migraine with or without aura 1 29.2 F2 CRP CD40LG APOH ALB ACE
44 retinal vascular disease 29.1 VEGFA CRP ALB ACE
45 lymphatic system disease 29.1 TP53 CRP CD40LG CD4 ALB
46 optic nerve disease 29.0 VEGFA CRP CD40LG CD4 ALB ACE
47 cerebrovascular disease 29.0 F2 CRP CD40LG APOH ACE
48 hypertensive encephalopathy 29.0 VEGFA F2 ALB ACE
49 thrombophlebitis 29.0 SERPINC1 F3 F2 CRP CD40LG APOH
50 cat-scratch disease 28.9 CRP CD40LG CD4 ACE

Graphical network of the top 20 diseases related to Papilledema:



Diseases related to Papilledema

Symptoms & Phenotypes for Papilledema

UMLS symptoms related to Papilledema:


edema

MGI Mouse Phenotypes related to Papilledema:

45 (show all 11)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.36 ACE ALB APOH ARSB CD4 CD40LG
2 hematopoietic system MP:0005397 10.29 ACE ARSB CD4 CD40LG F2 F3
3 immune system MP:0005387 10.28 ACE ALB CD4 CD40LG CRP F2
4 cardiovascular system MP:0005385 10.27 ACE ALB ARSB CD40LG CRP F2
5 mortality/aging MP:0010768 10.2 ACE ALB APOH CD4 CD40LG F2
6 integument MP:0010771 10.06 CD4 CD40LG F2 F3 IL1R1 IL1RN
7 liver/biliary system MP:0005370 9.97 ACE ALB IL1R1 NLRP3 OGG1 SERPINC1
8 nervous system MP:0003631 9.97 ARSB CD4 CD40LG F2 F3 IL1R1
9 neoplasm MP:0002006 9.8 ACE ALB F3 IL1R1 OGG1 TP53
10 normal MP:0002873 9.7 ALB CD4 F2 F3 IL1R1 NLRP3
11 renal/urinary system MP:0005367 9.28 ACE ALB ARSB CD40LG IL1R1 NLRP3

Drugs & Therapeutics for Papilledema

Drugs for Papilledema (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 102)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Minocycline Approved, Investigational Phase 4 10118-90-8 5281021
2
Doxycycline Approved, Investigational, Vet_approved Phase 4 564-25-0 54671203
3
Lymecycline Approved, Investigational Phase 4 992-21-2 5280963
4
Isotretinoin Approved Phase 4 4759-48-2 5282379 5538
5 Dermatologic Agents Phase 4
6 Pharmaceutical Solutions Phase 4
7 Mitogens Phase 4
8 Endothelial Growth Factors Phase 4
9
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 2, Phase 3 1177-87-3
10
Dexamethasone Approved, Investigational, Vet_approved Phase 2, Phase 3 50-02-2 5743
11
Ibuprofen Approved Phase 2, Phase 3 15687-27-1 3672
12
Guaifenesin Approved, Investigational, Vet_approved Phase 2, Phase 3 93-14-1 3516
13
Acetaminophen Approved Phase 2, Phase 3 103-90-2 1983
14
Codeine Approved, Illicit Phase 2, Phase 3 76-57-3 5284371
15
Naproxen Approved, Vet_approved Phase 2, Phase 3 22204-53-1 1302 156391
16
Bosentan Approved, Investigational Phase 3 147536-97-8 104865
17
Acetazolamide Approved, Vet_approved Phase 3 59-66-5 1986
18 Anti-Inflammatory Agents, Non-Steroidal Phase 2, Phase 3
19 Analgesics, Non-Narcotic Phase 2, Phase 3
20 Analgesics Phase 2, Phase 3
21 Anti-Inflammatory Agents Phase 2, Phase 3
22 HIV Protease Inhibitors Phase 2, Phase 3
23 Antiemetics Phase 2, Phase 3
24 Gastrointestinal Agents Phase 2, Phase 3
25
protease inhibitors Phase 2, Phase 3
26 Antineoplastic Agents, Hormonal Phase 2, Phase 3
27 glucocorticoids Phase 2, Phase 3
28 BB 1101 Phase 2, Phase 3
29 Hormone Antagonists Phase 2, Phase 3
30 Autonomic Agents Phase 2, Phase 3
31 Hormones Phase 2, Phase 3
32 Central Nervous System Depressants Phase 2, Phase 3
33 Fibrinolytic Agents Phase 2, Phase 3
34 Platelet Aggregation Inhibitors Phase 2, Phase 3
35 Narcotics Phase 2, Phase 3
36 Antipyretics Phase 2, Phase 3
37 Respiratory System Agents Phase 2, Phase 3
38 Cyclooxygenase Inhibitors Phase 2, Phase 3
39 Chlorpheniramine, phenylpropanolamine drug combination Phase 2, Phase 3
40 Analgesics, Opioid Phase 2, Phase 3
41 Antitussive Agents Phase 2, Phase 3
42 Endothelin Receptor Antagonists Phase 3
43 Antihypertensive Agents Phase 3
44 Natriuretic Agents Phase 3
45 Anticonvulsants Phase 3
46 diuretics Phase 3
47 Carbonic Anhydrase Inhibitors Phase 3
48
Nicotinamide Approved, Investigational Phase 2 98-92-0 936
49
Ranibizumab Approved Phase 2 347396-82-1 459903
50
Bevacizumab Approved, Investigational Phase 2 216974-75-3

Interventional clinical trials:

(show all 41)
# Name Status NCT ID Phase Drugs
1 Prospective Open-label Phase IV Trial to Investigate the Frequency of Optic Disc Swelling, Idiopathic Intracranial Hypertension and Dry Eye Symptoms Under Antiacne Medication Treatment Unknown status NCT02149615 Phase 4
2 Treatment of Diabetic Macular Edema (DME) With Intravitreal Anti-vascular Endothelial Growth Factor (Anti-VEGF) and Prompt Versus Deferred Focal Laser During Long-term Follow-up and Identification of Prognostic Retinal Markers Completed NCT03590444 Phase 4 Ranibizumab 0.5 MG/0.05 ML Intraocular Solution
3 Pegaptanib for Retinal Edema Secondary to Diabetic Vascular Disease(Preserve) Study Completed NCT01486238 Phase 4 Macugen® pegaptanib sodium
4 Ozurdex in Treatment of Macular Edema Post Membrane Peeling Completed NCT01273727 Phase 2, Phase 3 Dexamethasone;dexamethasone
5 A Multicenter, Double-blind, Randomized, Placebo-controlled Study of Weight-Reduction and/or Low Sodium Diet Plus Acetazolamide vs Diet Plus Placebo in Subjects With Idiopathic Intracranial Hypertension With Mild Visual Loss Completed NCT01003639 Phase 2, Phase 3 Acetazolamide;Placebo
6 Effect of Bosentan in Patients With Non Arteritic Ischemic Optic Neuropathy Recruiting NCT02377271 Phase 3 bosentan;placebo
7 Randomized Trial of Medical Therapy (MT) vs. MT Plus Optic Nerve Sheath Fenestration vs. MT Plus Ventriculoperitoneal Cerebrospinal Fluid Shunting in Subjects With Idiopathic Intracranial Hypertension and Moderate to Severe Visual Loss Active, not recruiting NCT03501966 Phase 3 Acetazolamide
8 Lowering Intracranial Pressure in Idiopathic Intracranial Hypertension: Assessing the Therapeutic Efficacy and Safety of an 11β-hydroxysteroid Dehydrogenase Type 1 Inhibitor (AZD4017). Phase II Study. Completed NCT02017444 Phase 2 AZD4017
9 Efficacy of Biweekly Ranibizumab (0.5 mg) for Exudative Macular Degeneration Retinal Edema Refractory to Anti-VEGF Therapy Comparing Syringe Preparation Time Using Ranibizumab Vial and Pre-filled Syringe Active, not recruiting NCT03071055 Phase 2 Ranibizumab Injection [Lucentis]
10 A Long-Term Outcome Study With the IL-1 Receptor Antagonist Anakinra/Kineret in Patients With Neonatal Onset Multisystem Inflammatory Disease (NOMID/CINCA Syndrome) A Therapeutic Approach to Study the Pathogenesis of This Disease Terminated NCT00069329 Phase 1, Phase 2 anakinra
11 Evaluation of the Feasibility, Safety and Efficacy of Venous Stenting for Internal Jugular Vein Stenosis Not yet recruiting NCT03373292 Phase 1
12 Ocular Point of Care Ultrasound (POCUS) to Detect Optic Disc Swelling in Comparison to Ophthalmologic Examination Unknown status NCT02992262
13 OCT Imaging of Papilledema in Pediatric Idiopathic Intracranial Hypertension Unknown status NCT02665858
14 Non-invasive Absolute Intracranial Pressure (ICP) Measurement in Patients With Open-angle Glaucoma and Papilledema Unknown status NCT02410148
15 Magnetic Resonance Venography Pre- and Post-Treatment in Patients With Idiopathic Intracranial Hypertension Unknown status NCT02394067
16 Stenting of Venous Sinus Stenosis for Medically Refractory Idiopathic Intracranial Hypertension Unknown status NCT02143258
17 Retinal Nerve Fibre Layer in Uveitic Secondary Glaucoma Completed NCT01170481
18 Digital Ocular Fundus Photography in the Emergency Department: A New Application for Telemedicine? Completed NCT00873613
19 LUMINOUS: Study to Observe the Effectiveness and Safety of Ranibizumab Through Individualized Patient Treatment and Associated Outcomes Completed NCT01318941 Ranibizumab
20 Clinical Outcomes of Prolensa (Bromfenac Ophthalmic Solution) 0.07% QD vs. Ilevro (Nepafenac Ophthalmic Suspension) 0.3% QD for Treatment of Ocular Inflammation Associated With Cataract Surgery Completed NCT01847638 Prolensa (bromfenac 0.07%);Ilevro (nepafenac 0.3%)
21 D-dimer and the Use of Anticoagulation in IIH Completed NCT03963336 Early Phase 1 LMWH;acetazolamide
22 The Role of Factor XIII Activation Peptide and D-dimer Values for the Diagnosis of Cerebral Venous Thrombosis Completed NCT00924859
23 Hyperphenylalaninemia in Cerebral Malaria Completed NCT00338520
24 The Role of Susceptibility to Thrombosis in the Pseudotumor Cerebri of Nephropathic Cystinosis: A Case-Control Study Completed NCT00071903
25 MRI for Non-invasive Evaluation of Brain Stress Completed NCT01898650
26 Cerebral Venous Sinus Thrombosis: Re-exploration of Clinical Assessment Recruiting NCT03273179
27 Evaluating Raised Intracranial Pressure Using MR Elastography Recruiting NCT03096743
28 Ocular Screening in Children and Young Adults at Risk for Increased Intracranial Pressure Recruiting NCT03286426
29 Measurement of Optic Nerve Sheath Diameter in Children Without the Increased Intracranial Pressure Recruiting NCT03178760
30 Diagnostic and Prognostic Biomarkers of Idiopathic Intracranial Hypertension Recruiting NCT04032379
31 Non-Invasive Measurement of Absolute Intracranial Pressure in Patients With Mass Effective Brain Tumors Recruiting NCT03641443
32 Effectiveness of Multimodal Imaging for the Evaluation of Retinal Oedema And New vesseLs in Diabetic Retinopathy Recruiting NCT03490318
33 Biomarker for Hypophosphatasia Disease AN INTERNATIONAL, MULTICENTER, EPIDEMIOLOGICAL PROTOCOL Recruiting NCT02603042
34 Prevalence of Ocular Manifestations in Inflammatory Rheumatic Diseases Active, not recruiting NCT03753893
35 Observational Study of Clinical Characteristics and Prognostic Factors of Korean Hypertensives Active, not recruiting NCT01861080
36 Validation of a Non-Invasive Intracranial Pressure (ICP) Device by Comparison With Implanted Intracranial Pressure Monitoring Instrumentation or Lumbar Puncture Active, not recruiting NCT03865576
37 A Single-Center Trial of High Frequency Pegaptanib for Rapid Restoration of VEGF Levels in Diabetic Retinal Edema Available NCT01487044 Macugen (Pegaptanib Sodium)
38 A Prospective, Randomized Controlled Study for the Efficacy and Safety of the Substitution of Pyrazinamide and Ethambutol With Moxifloxacin During the Intensive Phase of Treatment of Pulmonary Tuberculosis Not yet recruiting NCT04187469 Moxifloxacin, Isoniazid, Rifampicin;Rifampicin,Isoniazid,Pyrazinamide,Ethambutol
39 Operative Procedures vs. Endovascular Neurosurgery for Untreated Pseudotumor Trial (OPEN-UP) Not yet recruiting NCT02513914
40 Incidence and Causes of Disc Edema in Patients With Chronic Kidney Disease Withdrawn NCT00769834
41 Optic Nerve Head Quantification While Reducing Elevated Intracranial Pressure Withdrawn NCT02558309

Search NIH Clinical Center for Papilledema

Genetic Tests for Papilledema

Genetic tests related to Papilledema:

# Genetic test Affiliating Genes
1 Papilledema 29

Anatomical Context for Papilledema

MalaCards organs/tissues related to Papilledema:

40
Brain, Eye, Spinal Cord, Pineal, Retina, Endothelial, Kidney

Publications for Papilledema

Articles related to Papilledema:

(show top 50) (show all 2776)
# Title Authors PMID Year
1
A randomized, double blind, placebo-controlled trial on safety and efficacy of recombinant human insulin-like growth factor-I in children with growth hormone receptor deficiency. 54 61
7536209 1995
2
Current concepts of cerebrospinal fluid dynamics and the translaminar cribrosa pressure gradient: a paradigm of optic disk disease. 61
31449832 2020
3
Evaluation of the underlying causes of papilledema in children. 61
31836094 2019
4
[Amiodarone-induced optic neuropathy: A rare side effect]. 61
31561935 2019
5
Men Are from Mars, Idiopathic Intracranial Hypertension Is from Venous: The Role of Venous Sinus Stenosis and Stenting in Idiopathic Intracranial Hypertension. 61
31847040 2019
6
Pediatric liver diseases and ocular changes: What hepatologists and ophthalmologists should know and share with each other. 61
31843253 2019
7
Management of Peripapillary Choroidal Neovascular Membrane in Patients With Idiopathic Intracranial Hypertension. 61
30951011 2019
8
Point-of-care handheld ophthalmic ultrasound in the diagnosis and evaluation of raised intracranial pressure and Terson syndrome: a description of two cases. 61
31758491 2019
9
An Unusual Case of Unilateral Papilledema. 61
31763614 2019
10
Impact of Obstructive Sleep Apnea on Optic Nerve Function in Patients With Craniosynostosis and Recurrent Intracranial Hypertension. 61
31228466 2019
11
Papilledema and Peripheral Neuropathies. 61
31688711 2019
12
Papilledema Treated by Cranial Expansion in a 5-Year-Old Boy with Camurati-Engelmann Syndrome. 61
31635703 2019
13
Resolution of papilledema associated with cyclosporine use after change to tacrolimus. 61
31748372 2019
14
Peripheral retinal neovascularization in a patient with pilocytic astrocytoma. 61
31771349 2019
15
Bilateral exudative retinal detachment in undiagnosed ocular syphilis after treatment with corticosteroids. 61
31746221 2019
16
Ophthalmological management in craniosynostosis. 61
31574284 2019
17
Isolated Increased Intracranial Pressure and Unilateral Papilledema in an Infant With Traumatic Brain Injury and Nondepressed Basilar Skull Fracture. 61
31688803 2019
18
[Bilateral papilledema in a thirteen-year-old girl with Jeune syndrome]. 61
31708115 2019
19
Infantile Idiopathic Intracranial Hypertension: A Case Study and Review of the Literature. 61
31309848 2019
20
Ophthalmic adverse effects of lithium. 61
31743232 2019
21
Review of non-invasive intracranial pressure measurement techniques for ophthalmology applications. 61
31704702 2019
22
Psychiatric disorders are a common prognostic marker for worse outcome in patients with idiopathic intracranial hypertension. 61
31586855 2019
23
[Papilledema and thought disorder]. 61
30627763 2019
24
Microvascular Changes Associated with Optic Disc Drusen: Case Report 61
31650815 2019
25
Cytomegalovirus ventriculoencephalitis presenting with hydrocephalus in a patient with advanced HIV infection. 61
31798920 2019
26
Asymptomatic Versus Symptomatic Idiopathic Intracranial Hypertension in Children. 61
31259642 2019
27
Magnetic Resonance Imaging Findings in Pediatric Pseudotumor Cerebri Syndrome. 61
31303369 2019
28
Nonmydriatic Fundus Photography in Patients with Acute Vision Loss. 61
30575447 2019
29
Chiari 1 malformation and untreated sagittal synostosis: a new subset of complex Chiari? 61
31327038 2019
30
Outpatient Management of Headache after Pediatric Emergency Department Visit: Are we Missing Anything? 61
31348526 2019
31
Peripapillary Vessel Density Measured by Optical Coherence Tomography Angiography in Idiopathic Intracranial Hypertension. 61
30601283 2019
32
Magnetic Resonance Imaging of Idiopathic Intracranial Hypertension: Before and After Treatment. 61
31430269 2019
33
Hydrocephalus associated with multiple Tarlov cysts. 61
31383334 2019
34
Disseminated neurocysticercosis with bilateral papilledema: a case report. 61
31530282 2019
35
Optic canal size in idiopathic intracranial hypertension and asymmetric papilledema. 61
31176474 2019
36
Sonographic assessment of the optic nerve and the central retinal artery in idiopathic intracranial hypertension. 61
31540860 2019
37
Utility of Magnetic Resonance Imaging Features for Improving the Diagnosis of Idiopathic Intracranial Hypertension Without Papilledema: Comment. 61
31425437 2019
38
Utility of Magnetic Resonance Imaging Features for Improving the Diagnosis of Idiopathic Intracranial Hypertension Without Papilledema: Response. 61
31219894 2019
39
Optic Disc Hemangioblastoma with Papilledema in a Case of Von Hippel-Lindau Disease. 61
31511168 2019
40
Utility of Magnetic Resonance Imaging Features for Improving the Diagnosis of Idiopathic Intracranial Hypertension Without Papilledema. 61
30829949 2019
41
Usefulness of Standardized A-Scan technique in distinguishing papilledema from pseudopapilledema. 61
31154489 2019
42
Obstructive Sleep Apnea in Neuro-Ophthalmology. 61
30300256 2019
43
Clinicoradiological Discrepancy in Multisystem Langerhans Cell Histiocytosis with Central Nervous System Involvement. 61
31591994 2019
44
Serial Visual Evoked Potentials in Patients with Craniosynostosis and Invasive Intracranial Pressure Monitoring. 61
31461033 2019
45
Evaluation of optic nerve head changes with optic coherence tomography in patients with idiopathic intracranial hypertension. 61
30120685 2019
46
Transient vision loss after optic nerve sheath fenestration. 61
31537140 2019
47
Association of Intracranial Pressure and Spontaneous Retinal Venous Pulsation. 61
31498376 2019
48
Utility of Magnetic Resonance Imaging Features for Improving the Diagnosis of Idiopathic Intracranial Hypertension Without Papilledema: Comment. 61
31464806 2019
49
Papilledema and Bilateral Optic Neuropathy: Dual Mechanism for Visual Loss in a Patient with Leptomeningeal Carcinomatosis. 61
31659947 2019
50
An Ultrasound Vibro-Elastography Technique for Assessing Papilledema. 61
31122813 2019

Variations for Papilledema

Expression for Papilledema

Search GEO for disease gene expression data for Papilledema.

Pathways for Papilledema

Pathways related to Papilledema according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.78 VEGFA TP53 SERPINC1 F3 F2 APOH
2
Show member pathways
11.59 TP53 F2 CRP ALB
3 10.2 NLRP3 IL1R1 F2

GO Terms for Papilledema

Cellular components related to Papilledema according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 external side of plasma membrane GO:0009897 9.72 IL1R1 F2 CD40LG CD4 ACE
2 cell surface GO:0009986 9.7 VEGFA IL1R1 F3 CD40LG CD4 ARSB
3 endoplasmic reticulum lumen GO:0005788 9.65 SERPINC1 F2 CD4 ARSB ALB
4 extracellular space GO:0005615 9.65 VEGFA SERPINC1 IL1RN F3 F2 CRP
5 extracellular region GO:0005576 9.44 VEGFA SERPINC1 NLRP3 IL1RN IL1R1 F3

Biological processes related to Papilledema according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 inflammatory response GO:0006954 9.72 NLRP3 IL1RN IL1R1 CRP CD40LG
2 hemostasis GO:0007599 9.54 SERPINC1 F3 F2
3 negative regulation of fibrinolysis GO:0051918 9.4 F2 APOH
4 positive regulation of transcription from RNA polymerase II promoter in response to hypoxia GO:0061419 9.26 VEGFA TP53
5 positive regulation of peptidyl-tyrosine autophosphorylation GO:1900086 9.16 VEGFA ACE
6 regulation of blood coagulation GO:0030193 9.13 SERPINC1 F2 APOH
7 cytokine-mediated signaling pathway GO:0019221 9.1 VEGFA TP53 IL1RN IL1R1 F3 CD4

Molecular functions related to Papilledema according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 heparin binding GO:0008201 9.46 VEGFA SERPINC1 F2 APOH
2 identical protein binding GO:0042802 9.28 VEGFA TP53 SYP SERPINC1 NLRP3 CRP
3 protease binding GO:0002020 9.26 TP53 SERPINC1 IL1R1 F3

Sources for Papilledema

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....